PD-L1 expression assessed by immunohistochemical staining is used for the selection of immunotherapy in non-small cell lung cancer (NSCLC). Appropriate validation of PD-L1 expression in cytology specimens is important as cytology is often the only diagnostic material in NSCLC. In a previous study comprising two different cohorts of paired biopsies and cytological specimens, we found a fairly good cyto-histological correlation of PD-L1 expression in one, whereas only a moderate correlation was found in the other cohort. Therefore, that cohort with additional new cases was now further investigated for the impact of preanalytical factors on PD-L1 concordance in paired biopsies and cytological specimens. A total of 100 formalin-fixed paraffin-e...
PD-L1, as assessed by immunohistochemistry, is a predictive biomarker for immuno-oncology treatment ...
PD-L1, as assessed by immunohistochemistry, is a predictive biomarker for immuno-oncology treatment ...
Background: The PD-L1 assessment is mandatory for the selection of patients affected by advanced non...
PD-L1 expression assessed by immunohistochemical staining is used for the selection of immunotherapy...
PD-L1 expression assessed by immunohistochemical staining is used for the selection of immunotherapy...
INTRODUCTION: Programmed death-ligand 1 (PD-L1) expression is used for treatment prediction in non-s...
OBJECTIVES: PD-L1 immunohistochemistry (IHC) is an essential predictive biomarker for patients with ...
Programmed death ligand-1 (PD-L1) expression as determined by immunohistochemistry (IHC) is potentia...
Background: Lung cancer is the most common cause of cancer-related death worldwide and unfortunately...
Immunohistochemistry of the PD-L1 protein may be predictive for anti-PD-1 and anti-PD-L1 immunothera...
Introduction The assessment of PD-L1 expression by immunohistochemistry is mandatory for the adminis...
Assessment of programmed cell death ligand 1 (PD-L1) immunohistochemical staining is used for decisi...
Evaluation of programmed cell death ligand 1 (PD-L1) expression can be made on both resection specim...
Immunotherapy with checkpoint inhibitors, allowing recovery of effector cells function, has demonstr...
Programmed cell death ligand 1 (PD-L1) immunohistochemistry is used to determine which patients with...
PD-L1, as assessed by immunohistochemistry, is a predictive biomarker for immuno-oncology treatment ...
PD-L1, as assessed by immunohistochemistry, is a predictive biomarker for immuno-oncology treatment ...
Background: The PD-L1 assessment is mandatory for the selection of patients affected by advanced non...
PD-L1 expression assessed by immunohistochemical staining is used for the selection of immunotherapy...
PD-L1 expression assessed by immunohistochemical staining is used for the selection of immunotherapy...
INTRODUCTION: Programmed death-ligand 1 (PD-L1) expression is used for treatment prediction in non-s...
OBJECTIVES: PD-L1 immunohistochemistry (IHC) is an essential predictive biomarker for patients with ...
Programmed death ligand-1 (PD-L1) expression as determined by immunohistochemistry (IHC) is potentia...
Background: Lung cancer is the most common cause of cancer-related death worldwide and unfortunately...
Immunohistochemistry of the PD-L1 protein may be predictive for anti-PD-1 and anti-PD-L1 immunothera...
Introduction The assessment of PD-L1 expression by immunohistochemistry is mandatory for the adminis...
Assessment of programmed cell death ligand 1 (PD-L1) immunohistochemical staining is used for decisi...
Evaluation of programmed cell death ligand 1 (PD-L1) expression can be made on both resection specim...
Immunotherapy with checkpoint inhibitors, allowing recovery of effector cells function, has demonstr...
Programmed cell death ligand 1 (PD-L1) immunohistochemistry is used to determine which patients with...
PD-L1, as assessed by immunohistochemistry, is a predictive biomarker for immuno-oncology treatment ...
PD-L1, as assessed by immunohistochemistry, is a predictive biomarker for immuno-oncology treatment ...
Background: The PD-L1 assessment is mandatory for the selection of patients affected by advanced non...